



**Not for release, publication or distribution in the United States, Canada, Australia or Japan.**

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE RELEASE.

Public disclosure of inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014 on market abuse, as amended (market abuse regulation - MAR)

## ***Dermapharm Holding SE sets offer price at EUR 28.00 per share***

Grünwald, February 8, 2018 - Today, Dermapharm Holding SE (together with its consolidated subsidiaries, "Dermapharm", ISIN: DE000A2GS5D8) and the selling shareholder, Themis Beteiligungs-Aktiengesellschaft, have set the offer price at EUR 28.00 per share.

In total, all of the 13,455,000 offered shares in Dermapharm were placed. Thereof, 3,840,000 are newly issued shares from a capital increase and 9,615,000 are shares from the holdings of the selling shareholder, including 1,755,000 shares for over-allotments ("Greenshoe Option"). Assuming a full exercise of the Greenshoe Option, total gross proceeds will amount to approx. EUR 377 million. Thereof, gross proceeds of approx. EUR 108 million will be attributable to Dermapharm.

Trading in the shares on the regulated market (Prime Standard) of the Frankfurt Stock Exchange is expected to commence on February 9, 2018. The securities identification number (WKN) is A2GS5D, the international securities identification number (ISIN) is DE000A2GS5D8 and the trading symbol is DMP.

### **Contact**

cometis AG  
Claudius Krause

Phone: 0611-20585528  
Email: [ir@dermapharm.de](mailto:ir@dermapharm.de)

### **DISCLAIMER:**

*These materials may not be published, distributed or transmitted in the United States, Canada, Australia or Japan. These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities (the "Securities") of Dermapharm Holding SE (the "Company") in the United States, Australia, Canada or any other jurisdiction in which such offer or solicitation is unlawful. The Securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan subject to certain exceptions.*

*The Securities of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). The Securities of the Company have not been, and will not be, registered under the Securities Act. There will be no public offering of the securities in the United States. Any sale in the United States of the Securities mentioned in this communication will be made solely to "qualified institutional buyers" as defined in, and in reliance on, Rule 144A under the Securities Act.*



**Not for release, publication or distribution in the United States, Canada, Australia or Japan.**

*This publication constitutes neither an offer to sell nor a solicitation to buy securities Dermapharm Holding SE. The offer is being made solely by means of, and on the basis of, the published securities prospectus (including any amendments thereto, if any). An investment decision regarding the publicly offered securities of Dermapharm Holding SE should only be made on the basis of the securities prospectus. The securities prospectus has been approved by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin)) and is available free of charge from Dermapharm Holding SE, Lil-Dagover-Ring 7, 82031 Grünwald, Germany, or on the Dermapharm Holding SE website.*

*In the United Kingdom, this document is only being distributed to and is only directed at persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or (ii) are persons falling within Article 49(2)(a) through (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.*

*In connection with the placement of the offer shares Joh. Berenberg, Gossler & Co. KG will act as the stabilization manager (the "Stabilization Manager") and may, as Stabilization Manager, and acting in accordance with legal requirements (Article 5 para. 4 and 5 of the Market Abuse Regulation (EU) No 596/2014 in conjunction with Articles 5 through 8 of the Commission Delegated Regulation (EU) 2016/1052), make over-allotments and take stabilization measures to support the market price of the Company's shares and thereby counteract any selling pressure.*

*The Stabilization Manager is under no obligation to take any stabilization measures. Therefore, stabilization may not necessarily occur and may cease at any time. Such measures may be taken on the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse) from the date when trading in the shares of the Company is commenced on the regulated market segment (regulierter Markt) of the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse) and must be terminated no later than 30 calendar days after this date (the "Stabilization Period"). Stabilization transactions aim at supporting the market price of the Company's shares during the Stabilization Period. These measures may result in the market price of the Company's shares being higher than would otherwise have been the case. Moreover, the market price may temporarily be at an unsustainable level.*